Avid Bioservices Inc (CDMO)

[nuke661]

mrpatinmn,

You're welcome. I am letting the past predict the future and that's why I keep buying the stock.

The list of past events that keep me buying:
1) Outstanding 2nd line NSCLC trial data: FDA approved progression to PIII trials based on PII data that indicated a 60% improvement in MOS. Show me another trial that has better data than this and consider on top of that the numbers were a result our our forced conservatively reconstituted trial population. The world at large will have to make their own assessment of what may or may not have been actually occurring in the trials prior to the incident. My personal opinion is that most of the retail investment and trading world hasn't a clue and could care less. Hence why we need another landmark event to get us going again. Damage done to reputation but not to Bavi's actual efficacy.
2) Outstanding Breast Cancer data from a US IST site that (IMO) shreds all the naysayers claims about the previous MBC data being obtained from questionable overseas sources. >80% ORR rates in a population that typically is only expected to have ~40 something % ORR rates.
3) We have a FDA PIII trial design approved for gliabastoma multiforme orphan drug waiting for a sugar daddy to sponsor it. The company, sad to say, doesn't have the resources to push this any further without seriously compromising the ability to push forward the Bavi platform which in the real world helps more people and represents more money for us stockholders.
4) Steve King is using descriptive statements regarding the liver cancer IST that I don't recall since the 2nd line data descriptions building up last summer to the wonderful data news when the 2nd line was stated to be >100 % improvement in OSS.
5) We've kept ownership control of the entire Bavi IP. Of course at a cost of dilution. I'll take the dilution of the ATM over the alternatives presented here for the purpose of financing product development balanced against the potential returns that I see are still very probable for the reasons in 1, 2 & 4 and item 3 is always waiting to surprise us. Many here have presented very good reasons why dilution is preferable to putting up IP as collateral for loans and for selling it before its ripe or before someone is willing to pony up the dough for a broad based cancer platform that is still playing out regarding its breadth. You've got to remember that Steve hasn't been hedging his adjectives for liver cancer like they were doing for the 1st line NSCLC.

IMO if people cannot see these things as the overriding positives in this high risk speculative biotech world then I'm really at a loss as to why they stay invested in PPHM. At least I'm at a loss for those who say they are invested. I understand there are large short positions in this stock and those people are out to trash it just like we who believe in the potential like to defend it.